Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Verichem calibration verifiers for cholinesterase testing

June 2023—Verichem Laboratories offers multilevel calibration verification materials for cholinesterase activity as part of its liquid-stable and ready-to-use Enzyme ER Verifier kit. The verifiers are designed to include at least one concentration level of enzyme activity within the normal range and intended to be treated as patient specimens. The material’s protein balance, pH, and ion content are constant across concentration levels. The kit material also contains multilevel assigned activities for alanine aminotransferase, alkaline phosphatase, alpha-amylase, aspartate aminotransferase, creatine phosphokinase, gamma-glutamyl transferase, lactate dehydrogenase, and lipase. Each kit has 5 mL of material for each of the six levels and a shelf-life and open-vial stability of 18 months.

 

Labcorp gets exclusive license for Proteomedix prostate cancer test

June 2023—Proteomedix (Schlieren, Switzerland) announced an exclusive license agreement in which Labcorp will develop and commercialize its Proclarix prostate specific antigen test in the United States. Proclarix is performed using the same blood sample as a PSA test and is designed to help determine the risk of clinically significant prostate cancer for men who have an elevated total PSA and a digital rectal examination finding that indicates elevated prostate volume but who are not suspected of having cancer.

 

Trane Technologies acquires Helmer Scientific

June 2023—Trane Technologies has acquired Helmer Scientific. Trane says the acquisition will broaden its capabilities in precision temperature control and its existing portfolio of life science solutions under the Farrar brand. Trane will leverage its operating system and expertise in sustainability, services, worldwide distribution, and commercialization to accelerate Helmer’s continued growth.

 

Quansys Biosciences bovine-specific ELISAs

June 2023—Quansys Biosciences has developed Q-Plex Bovine Cytokine Panel 1 (5-plex), an ELISA kit that can measure five levels of bovine and African water buffalo cytokines in plasma, serum, and cell culture supernatants. Each kit contains a 96-well plate featuring the relevant biomarker panel in each well and all reagents required to perform testing.

 

FDA clears Panther Fusion SARS-CoV-2, flu, RSV assay

June 2023—Hologic announced the FDA has granted 510(k) clearance for its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. This molecular diagnostic test, previously under EUA, detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus. It runs on the Panther Fusion system, which provides initial results in about three hours and can process more than 1,000 tests in 24 hours.

 

Beckman Coulter unveils DxI 9000 Access

June 2023—Beckman Coulter unveiled its DxI 9000 Access immunoassay analyzer. The analyzer can run up to 215 tests per hour per square meter and does not require daily maintenance; its weekly maintenance time is less than 15 minutes. It is available in most countries.

 

BD gets clearance for MRSA diagnostics AI software

June 2023—BD received FDA 510(k) clearance for the BD Kiestra methicillin-resistant Staphylococcus aureus imaging application, which uses artificial intelligence to automate the task of inspecting Petri dishes to determine if there is bacterial growth. The application can evaluate single specimens or group together a large volume of plates with nonsignificant growth for batch review and release negative results. It uses AI algorithms to look for specific culture characteristics on the BBL Chromagar MRSA II plate. Based on that information and analysis by BD Synapsys informatics, plate images are automatically organized and sorted into meaningful worklists, the company says.

 

Randox introduces PSA and BNP control

June 2023—Randox Labs has released two new products, a prostate-specific antigen and brain natriuretic peptide control. The liquid-frozen PSA is manufactured using human serum and has an open-vial stability of 30 days at 2°–8°C and a shelf life of one year from the date of manufacture. The control is optimized for use with Roche systems but is also suitable for use across a variety of other platforms, the company says.

 

Sarstedt launches NFT urine collection system

May 2023—Sarstedt’s new Needle-Free Transfer Urine Collection System is a closed urine collection system for needle-free transfer of urine from the needle-free cup or urine collection container to a Urine Monovette. The cup and collection container feature an integrated transfer unit with a pierceable membrane. After collecting a sample with the Urine Monovette, the membrane reseals immediately, ensuring hygienic and repeatable sample collection with no risk of accidental needle sticks. A 100-mL urine cup and 3-L urine container are available.

Quest to acquire Haystack Oncology

May 2023—Quest Diagnostics and Haystack Oncology, an early-stage oncology company focused on minimal residual disease testing, announced on April 27 a definitive agreement for Quest to acquire Haystack in an all-cash equity transaction.

MARKETPLACE

TRENDING